genOway SA

Paris Stock Exchange ALGEN.PA

genOway SA Price to Earnings Ratio (P/E) on February 05, 2025: 18.67

genOway SA Price to Earnings Ratio (P/E) is 18.67 on February 05, 2025, a -5.69% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

genOway SA 52-week high Price to Earnings Ratio (P/E) is 22.46 on June 07, 2024, which is 20.29% above the current Price to Earnings Ratio (P/E).
genOway SA 52-week low Price to Earnings Ratio (P/E) is 16.17 on January 22, 2025, which is -13.40% below the current Price to Earnings Ratio (P/E).
genOway SA average Price to Earnings Ratio (P/E) for the last 52 weeks is 19.48.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Paris Stock Exchange: ALGEN.PA

genOway SA

CEO	Dr. Alexandre Fraichard
IPO Date	May 7, 2007
Location	France
Headquarters	Technopark 2
Employees	124
Sector	Healthcare
Industries Biotechnology 3D Printing Drones Personal Care Pet Food Pharmaceuticals Robotics Vaccines

Description

genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.

Key trends

Past 5 years